Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075993 · ClinicalTrials.gov registry record · Phase 1
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
A Phase 1 study of Gastric Cancer and Metastatic Uveal Melanoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 352
- Enrollment target
- 1
- Study location
NCT05075993 is a Phase 1 study of Gastric Cancer and Metastatic Uveal Melanoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 352 participants, above the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05075993, a Phase 1 study of Gastric Cancer and Metastatic Uveal Melanoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 352 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND). Lvygen Biopharma will provide as investigational supply LVGN3616, LVGN6051 and LVGN7409 at no cost to the patients on this study. This study will explore antitumor activity of four LVGN3616 and LVGN6051 based regimens in seven selected tumor types:
Conditions Studied
Interventions
- DRUG LVGN3616 + LVGN6051 + Nab-Paclitaxel
- DRUG LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
- DRUG LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- DRUG LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2027-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05075993
The ClinicalTrials.gov registry entry for NCT05075993 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (11% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which LVGN3616 + LVGN6051 + Nab-Paclitaxel is the first listed.
NCT05075993 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05075993 about?
NCT05075993 is a clinical study titled "Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors". This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND). Lvygen Biopharma will provide as investigational supply LVGN3616, LVGN6051 and LVGN7409 a...
What is the current status of trial NCT05075993?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 352 participants. The study started on 2021-11-12. Estimated completion is 2027-02-02.
What conditions does trial NCT05075993 study?
This clinical trial studies the following conditions: Gastric Cancer, Metastatic Uveal Melanoma, Metastatic Soft Tissue Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Head and Neck Carcinoma.
What interventions are being tested in trial NCT05075993?
The interventions under investigation include: LVGN3616 + LVGN6051 + Nab-Paclitaxel (DRUG), LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (DRUG), LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel (DRUG), LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT05075993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05075993 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.